Apexigen, Inc.

Medimmune Limited

Xiaodong Yang

Guo-Liang Yu

Weimin Zhu

Yongke Zhang

Gadi Gazit-Bornstein

Susan Ann Cartlidge

Christine Tan

David William Tonge

Olivia Raeber

Pia Björck

Erin Filbert

Provided are anti-programmed death-ligand 1 (PD-L1) monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and oncological diseases. Specifically, high affinity, humanized anti-PD-L1 antibodies are provided.

Anti-PD-L1 antibodies and methods of use

The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Anti-RANKL antibodies and methods of use

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

Insulin-like growth factor antibodies and uses thereof

Growing community of inventors

Palo Alto, CA, United States of America

Xiaodong Yang